Tuesday, November 5, 2024
HomeTagsBASEL

BASEL

Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics

Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced the completion of a CHF 15.5 million (EUR 15.2...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics